

10. (amended) The substrate platform of claim 1 wherein the microfluidic analysis platform comprising a non-linear meandering flow path.

26. (amended) The substrate platform of claim 1 wherein the sample analysis area comprises one or more biomolecules.

27. (amended) The substrate platform of claim 1 wherein the sample analysis area comprises one or more nucleic acid compounds or peptide compounds.

43. (amended) A method for sample analysis comprising applying a sample to the substrate platform of claim 1, and evaluating the sample.

REMARKS

For the sole purpose of reducing initial claims fees, claims 6, 7, 11-25, 30-33, 36-42, 45-46, and 49-50 have been canceled without prejudice, and claims 3-5, 9, 10, 26, 27 and 43 have been amended. Applicants expressly reserve all rights to prosecute the subject matter of those cancelled and amended claims, either in the present application or suitable continuing application.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman IP Group
P.O. Box 9169
Boston, MA 02209
(617) 523-3400

MARKED VERSION TO SHOW CHANGES

3. (amended) The substrate platform of claim 1 [or 2], wherein a first substrate platform part in a planar surface thereof has depressed a defined channel system and a second substrate platform part is a planar substrate adhered to the first part planar surface.
4. (amended) The substrate platform of claim [2 or] 3, wherein the two parts are adhered together with an adhesive.
5. (amended) The substrate platform of claim 2 [any one of claims 2 through 4], wherein the planar substrate is a transparent plastic member.
9. (amended) The substrate platform of claim 1 [any one of claims 1 through 8] wherein the microfluidic analysis platform comprises the sample analysis area.
10. (amended) The substrate platform of claim 1 [any one of claims 1 through 9] wherein the microfluidic analysis platform comprising a non-linear meandering flow path.
26. (amended) The substrate platform of claim 1 [any one of claims 1 through 25] wherein the sample analysis area comprises one or more biomolecules.
27. (amended) The substrate platform of claim 1 [any one of claim 1 through 26] wherein the sample analysis area comprises one or more nucleic acid compounds or peptide compounds.
43. (amended) A method for sample analysis comprising applying a sample to the substrate platform of claim 1 [any one of claims 1 through 40], and evaluating the sample.